genet
evolut
infecti
diseas
http
dx
histori
develop
infecti
diseas
genom
close
associ
human
genom
project
hgp
seri
import
discuss
hgp
made
led
appoint
special
nation
research
council
nrc
committe
nation
academi
scienc
address
need
concern
impact
leadership
fund
sourc
committe
recommend
unit
state
begin
hgp
emphas
need
technolog
improv
effici
gene
map
sequenc
data
analysi
capabl
order
understand
potenti
function
human
gene
compar
sequenc
analys
also
advis
hgp
must
restrict
human
genom
includ
model
organ
includ
mous
bacteria
yeast
fruit
fli
worm
meantim
offic
technolog
assess
ota
us
congress
also
issu
similar
report
support
hgp
depart
energi
doe
nation
institut
health
nih
jointli
present
initi
plan
hgp
octob
sanger
centerinstitut
hinxton
uk
offici
open
join
hgp
cost
dna
sequenc
per
base
initi
aim
reduc
cost
less
per
base
largescal
sequenc
sequenc
cost
gradual
declin
subsequ
year
nation
human
genom
research
institut
nhgri
challeng
scientist
achiev
human
genom
gbhaploid
genom
genom
meet
need
genom
medicin
earli
illumina
announc
compani
would
begin
produc
new
system
deliv
full
coverag
human
genom
less
first
complet
genom
sequenc
bacteriophag
kb
sanger
group
complet
genom
sequenc
polyomaviru
kb
publish
human
epsteinebarr
viru
kb
genom
determin
first
complet
freeliv
organ
genom
haemophilu
influenza
mb
sequenc
wholegenom
shotgun
approach
second
sequenc
bacteri
genom
mycoplasma
genitalium
kb
complet
less
month
year
use
approach
doe
first
start
microbi
genom
program
mgp
companion
hgp
initi
focu
nonpathogen
microb
along
develop
hgp
exponenti
growth
number
complet
sequenc
freeliv
organ
genom
fungal
genom
initi
fgi
establish
acceler
slow
pace
fungal
genom
sequenc
sinc
report
genom
saccharomyc
cerevisia
one
major
interest
sequenc
organ
import
humanhealth
commerci
activ
explos
number
sequenc
genom
thank
develop
next
generationesequenc
method
mani
genomebas
studi
becom
popular
compar
year
ago
complet
genom
project
document
gold
genom
onlin
databas
contain
inform
genomesequenc
project
complet
august
genom
human
malaria
parasit
plasmodium
falciparum
major
mosquito
vector
anophel
gambia
publish
histor
effort
sequenc
malaria
genom
began
take
advantag
clone
deriv
laboratoryadapt
strain
notabl
mani
parasit
complex
life
cycl
involv
vertebr
invertebr
host
difficult
maintain
laboratori
import
human
pathogen
parasit
trypanosom
leishmania
schistosom
either
complet
partial
sequenc
meantim
genom
sequenc
aed
aegypti
primari
vector
yellow
fever
dengu
fever
publish
genom
size
mb
mosquito
vector
time
larger
previous
sequenc
genom
malaria
vector
gambia
genom
consist
transpos
element
genom
sequenc
bodi
lous
pediculu
humanu
humanu
obligatori
parasit
human
main
vector
epidem
typhu
rickettsia
prowazekii
relaps
fever
borrelia
recurrenti
trench
fever
bartonella
quintana
report
mb
genom
smallest
among
known
insect
genom
subsequ
vector
genom
publish
genomesequenc
project
import
human
diseas
vector
progress
includ
culex
pipien
mosquito
vector
west
nile
viru
ixod
scapulari
tick
vector
lyme
diseas
babesia
anaplasma
challeng
sequenc
genom
insect
vector
much
greater
microb
exampl
genom
tick
estim
gb
may
signific
proport
repetit
dna
sequenc
may
problem
genom
assembl
furthermor
evolutionari
distanc
among
insect
speci
may
also
affect
homologybas
gene
predict
import
understand
sequenc
divers
within
speci
perform
de
novo
sequenc
refer
genom
perspect
human
health
true
host
pathogen
goal
genom
project
find
genet
variant
frequenc
least
human
popul
studi
one
similar
effort
human
pathogen
nih
influenza
genom
sequenc
project
project
began
novemb
seven
human
influenza
isol
complet
sequenc
deposit
genbank
databas
may
human
avian
isol
complet
sequenc
includ
spanish
influenza
viru
databas
human
immunodefici
viru
hiv
hepat
c
viru
also
establish
human
studi
microb
focus
diseasecaus
organ
interest
resid
microorgan
also
grow
fact
estim
human
bodi
colon
least
time
prokaryot
eukaryot
microorgan
number
human
cell
suggest
human
genom
project
sequenc
human
microbiom
highli
variabl
intestin
microbi
flora
among
normal
individu
well
document
therefor
human
microbiom
project
hmp
initi
nih
late
analysi
data
healthi
adult
male
femal
bodi
site
month
publish
complet
ongo
genom
project
tabl
provid
enorm
opportun
discoveri
novel
vaccin
drug
target
human
pathogen
well
improv
diagnosi
discoveri
infecti
agent
develop
new
strategi
invertebr
vector
control
specif
exampl
provid
illustr
inform
provid
variou
genom
project
may
help
achiev
goal
promot
human
health
meningococc
isol
produc
one
antigen
distinct
capsular
polysaccharid
five
b
c
commonli
associ
diseas
polysaccharid
capsul
import
meningococci
escap
complementmedi
kill
convent
vaccin
consist
conjug
capsular
polysaccharid
carrier
protein
meningococcu
serogroup
c
clinic
success
approach
fail
produc
clinic
use
vaccin
serogroup
b
menb
capsul
polysaccharid
acid
menb
ident
human
polysial
acid
therefor
poorli
immunogen
altern
vaccin
consist
outermembran
vesicl
omv
success
develop
control
menb
outbreak
area
epidem
domin
one
particular
strain
signific
limit
type
vaccin
immun
respons
strain
specif
mostli
direct
porin
protein
pora
vari
substanti
express
level
sequenc
across
strain
complet
genom
sequenc
virul
menb
strain
revers
vaccinolog
approach
appli
develop
univers
menb
vaccin
novarti
bioinformat
search
surfac
expos
antigen
may
suitabl
vaccin
candid
due
potenti
readili
recogn
immun
system
open
read
frame
orf
select
total
orf
genom
eventu
five
antigen
chosen
vaccin
compon
base
seri
criteria
includ
abil
candid
express
escherichia
coli
recombin
protein
candid
confirm
surfac
exposur
immunolog
analys
abil
induc
protect
antibodi
experiment
anim
candid
conserv
antigen
within
panel
divers
meningococc
strain
primarili
diseaseassoci
menb
strain
vaccin
formul
consist
fusion
protein
fusion
protein
nada
omv
new
zealand
menzb
vaccin
strain
contain
immunogen
pora
initi
phase
ii
clinic
result
adult
infant
show
vaccin
could
induc
protect
immun
respons
three
divers
menb
strain
subject
follow
three
vaccin
four
vaccin
vaccin
bexsero
approv
usa
countri
natur
product
especi
microbi
secondari
metabolit
import
sourc
bioactiv
compound
actinomycet
main
sourc
naturalproduct
discoveri
bacteria
consequ
high
rediscoveri
rate
known
compound
scaffold
inevit
activitybas
screen
genom
mine
gene
cluster
produc
secondari
metabolit
new
approach
overcom
problem
exampl
antibiot
clostrubin
discov
search
novel
compound
clostridium
beijerinckii
due
presenc
sever
cryptic
gene
cluster
secondari
metabolit
biosynthesi
genom
mine
start
genomewid
search
highli
conserv
member
requir
biosynthesi
gene
cluster
comput
program
support
predict
operon
help
assign
boundari
newli
identifi
biosynthesi
gene
cluster
largescal
highthroughput
genom
mine
genet
potenti
produc
phosphon
acid
screen
actinomycet
achiev
believ
phosphon
would
greater
potenti
becom
pharmaceut
past
commerci
rate
fosfomycin
compar
averag
natur
product
whole
addit
bioinformat
discoveri
phosphon
biosynthet
loci
well
establish
two
previous
character
phosphon
biosynthet
pathway
start
phosphoenolpyruv
pep
mutas
encod
pepm
among
actinomycet
strain
confirm
pepm
polymeras
chain
reaction
pcr
screen
genom
sequenc
divers
collect
phosphon
biosynthet
gene
cluster
identifi
within
strain
remark
distinct
cluster
would
direct
synthesi
unknown
compound
character
strain
within
five
group
result
discoveri
argolapho
interest
compound
includ
valinopho
phosphonocystoxim
argolapho
show
broadspectrum
antibacteri
activ
salmonella
typhimurium
e
coli
staphylococcu
aureu
target
essenti
pathway
necessari
suffici
requir
effect
antimicrobi
agent
identif
essenti
gene
complet
sequenc
genom
activ
pursu
variou
approach
indispens
fatti
acid
synthas
fa
pathway
bacteria
regard
promis
target
develop
antimicrobi
agent
subcellular
organ
fatti
acid
biosynthesi
compon
differ
mammal
type
fa
bacteria
dissoci
type
ii
fa
rais
likelihood
host
specif
target
drug
comparison
avail
genom
sequenc
variou
speci
prokaryot
reveal
highli
conserv
fa
ii
system
suggest
antimicrobi
agent
broad
spectrum
addit
comput
analys
new
member
fa
ii
system
discov
differ
bacteri
speci
one
protein
compon
system
fabi
target
antituberculosi
drug
isonizid
gener
antibacteri
antifung
agent
triclosan
systemat
screen
natur
product
extract
merck
team
identifi
potent
broadspectrum
antibiot
platensimycin
deriv
streptomyc
platensi
select
fabfb
inhibitor
fa
ii
system
treatment
platensimycin
erad
aureu
infect
mice
platensimycin
crossresist
antibioticresist
strain
vitro
includ
methicillinresist
aureu
vancomycinintermedi
aureu
vancomycinresist
enterococci
toxic
observ
use
cultur
human
cell
line
activ
platensimycin
affect
presenc
human
serum
studi
howev
fa
ii
system
appear
dispens
anoth
gramposit
bacterium
streptococcu
agalactia
exogen
fatti
acid
avail
human
serum
suscept
inhibitor
target
fa
ii
system
indic
heterogen
fatti
acid
synthesi
acquir
exogen
fatti
acid
among
gramposit
pathogen
compar
genom
approach
may
use
identifi
develop
strategi
target
salvag
pathway
agalactia
altern
similar
approach
describ
earlier
menb
vaccin
may
also
appli
agalactia
group
b
streptococcu
emerg
drugresist
malaria
chloroquin
sulfadoxine
pyrimethamin
occur
western
cambodia
greater
mekong
subregion
gmsr
includ
cambodia
lao
myanmar
thailand
vietnam
africa
find
artemisininresist
malaria
cambodia
gmsr
rais
concern
regard
global
spread
parasit
number
studi
includ
popul
genet
laboratorybas
investig
conduct
reliabl
molecular
marker
identifi
major
breakthrough
report
earli
clinic
artemisinin
resist
defin
reduct
parasiteclear
rate
express
increas
parasiteclear
halflif
persist
microscop
detect
parasit
day
artemisininbas
combin
therapi
act
although
artemisinin
thought
broadstag
specif
malaria
throughout
life
cycl
show
artemisininresist
parasit
decreas
artemisinin
suscept
ring
stage
demonstr
ringstag
surviv
assay
rsa
h
vitro
laboratorybas
approach
conduct
time
populationbas
genomewid
associ
studi
gwa
clearli
identifi
gene
respons
artemisinin
resist
year
artemisininresist
parasit
line
select
cultur
artemisininsensit
clone
doseescal
regimen
artemisinin
eight
mutat
seven
gene
eventu
select
result
base
wholegenom
sequenc
analysi
sibl
clone
cultur
without
artemisinin
averag
nucleotid
coverag
respect
examin
whether
vitro
select
mutat
associ
artemisinin
resist
cambodia
sequenc
polymorph
seven
gene
analyz
cultureadapt
clinic
isol
relat
rsa
h
polymorph
gene
show
signific
associ
rsa
h
surviv
rate
total
four
mutant
allel
harbor
singl
nonsynonym
snp
within
kelch
repeat
ctermin
domain
identifi
confirm
polymorph
molecular
marker
clinic
artemisinin
resist
parasiteclear
halfliv
patient
correl
allel
patient
carri
parasit
wildtyp
allel
other
carri
parasit
one
three
singl
nonsynonym
snp
n
n
n
parasiteclear
halflif
patient
wildtyp
parasit
significantli
shorter
median
h
three
mutant
allel
median
h
subsequ
clinic
studi
valid
associ
propel
mutat
artemisinin
resist
earli
mathemat
model
malaria
control
suggest
vulner
element
malaria
cycl
survivorship
adult
femal
mosquito
therefor
insect
control
import
part
reduc
transmiss
use
ddt
indoor
residu
spray
global
malaria
erad
program
reduc
popul
risk
malaria
compar
engin
genet
modifi
mosquito
refractori
malaria
infect
appear
altern
approach
given
environment
impact
ddt
emerg
insecticideresist
insect
vector
biolog
network
vbn
form
propos
plan
achiev
three
major
goal
develop
basic
tool
stabl
transform
anophelin
mosquito
year
engin
mosquito
incap
carri
malaria
parasit
run
control
experi
test
drive
engin
genotyp
wild
mosquito
popul
proofofconcept
experi
achiev
first
two
aim
gambia
genom
complet
sequenc
progress
rel
slow
genom
loci
gambia
respons
p
falciparum
resist
identifi
survey
mosquito
popul
west
african
malaria
transmiss
zone
candid
gene
anophel
plasmodiumrespons
leucinerich
repeat
discov
subsequ
resist
gene
also
identifi
studi
genet
basi
resist
malaria
parasit
immun
mosquito
vector
import
control
malaria
transmiss
perhap
immedi
impact
complet
sequenc
pathogen
genom
infecti
diseas
diagnosi
inform
may
great
import
public
health
newli
emerg
reemerg
pathogen
discov
exampl
describ
novel
swineorigin
influenza
viru
soiv
emerg
spring
mexico
subsequ
discov
specimen
two
unrel
children
san
diego
area
midapril
sampl
posit
influenza
neg
human
subtyp
complet
genom
sequenc
realtim
pcrebas
diagnost
assay
releas
public
late
april
outbreak
evolv
rapidli
declar
highest
phase
worldwid
pandem
alert
june
soiv
three
genom
segment
ha
np
ns
classic
north
american
swine
lineag
two
segment
pa
north
american
avian
lineag
one
segment
season
notabl
two
segment
na
eurasian
swine
lineag
avail
influenza
genom
databas
diagnost
assay
distinguish
previou
season
soiv
easili
accomplish
comprehens
pathogen
genom
databas
use
infecti
diseas
diagnosi
also
novel
pathogen
discoveri
homolog
sequenc
within
famili
among
differ
famili
member
import
new
pathogen
identif
even
advent
third
generationesequenc
technolog
de
novo
pathogen
discoveri
may
also
complic
coexist
microorgan
commens
bacteria
human
bodi
without
prior
knowledg
microorgan
one
may
misl
microarraybas
assay
design
virochip
use
help
discov
sar
conoronaviru
virochip
contain
highli
conserv
sequenc
everi
fulli
sequenc
refer
viral
genom
genbank
comput
search
conserv
perform
across
known
viral
famili
microarray
hybrid
reaction
deriv
viral
isol
cultiv
sar
sever
acut
respiratori
syndrom
patient
reveal
strongest
hybrid
array
element
belong
famili
astrovirida
coronavirida
align
oligonucleotid
probe
highest
signal
show
four
hybrid
oligonucleotid
astrovirida
one
oligonucleotid
avian
infecti
bronchiti
viru
avian
coronaviru
share
core
consensu
motif
span
nucleotid
interestingli
known
previous
bioinformat
analys
sequenc
present
utr
astrovirus
avian
infecti
bronchiti
viru
equin
rhinoviru
therefor
new
member
coronaviru
identifi
uniqu
hybrid
pattern
subsequ
confirm
find
seventh
human
oncogen
viru
merkel
cell
polyomaviru
mcv
anoth
exampl
conserv
sequenc
import
novel
pathogen
discoveri
mcv
etiolog
agent
merkel
cell
carcinoma
mcc
rare
aggress
skin
cancer
neuroendocrin
origin
two
cdna
librari
deriv
mcc
tumor
subject
highthroughput
sequenc
nextgener
sequenc
nearli
sequenc
read
gener
major
sequenc
deriv
human
origin
remov
analys
one
remain
cdna
homolog
antigen
two
known
polyomavirus
one
addit
cdna
subsequ
identifi
part
mcv
sequenc
complet
viral
sequenc
known
later
analys
show
mcc
integr
mcv
human
genom
monoclon
viral
integr
reveal
pattern
southern
blot
analysi
control
tissu
low
copi
number
mcv
infect
interest
unexpect
discoveri
malign
transform
hymenolepi
nana
human
tape
worm
human
host
report
convent
next
generationesequenc
approach
initi
examin
hivinfect
man
reveal
extens
lymphadenopathi
h
nana
egg
blastocysti
homini
cyst
found
stool
diseas
progress
death
despit
antiparasit
antiretrovir
treatment
histolog
examin
biopsi
lymph
node
reveal
prolif
cell
overt
malign
featur
monomorph
morpholog
featur
characterist
stem
cell
high
nucleustocytoplasm
ratio
howev
small
cell
size
suggest
infect
unfamiliar
possibl
unicellular
eukaryot
organ
infect
plasmodi
slime
mold
rather
h
nana
consid
promin
syncytia
format
primit
appear
atyp
cell
lack
architectur
identifi
tapeworm
tissu
pcr
screen
suggest
cell
h
nana
next
generationegenom
sequenc
compar
analysi
reveal
h
nana
variant
harbor
mutat
typic
found
cancer
next
generationesequenc
technolog
gradual
appli
diagnosi
monitor
infecti
diseas
includ
genotyp
resist
test
direct
detect
unknown
diseaseassoci
pathogen
without
cultur
investig
microbi
popul
divers
host
strain
type
howev
promis
next
generationesequenc
approach
clinic
diagnosi
requir
improv
autom
standard
technic
bioinformat
procedur
practic
issu
cost
turnaround
time
expect
effort
varieti
genom
project
may
improv
human
health
socioeconom
issu
discuss
chapter
may
substanti
addit
tremend
amount
inform
deriv
project
also
pose
challeng
scientist
well
nonscientist
follow
understand
